In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...

The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...

The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of ...

The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of neovascular AMD. Primary endpoints include the safety and tolerability of ...

“The recent positive results from our ODYSSEY trial establish CLS-AX as a Phase 3 ready asset in the large and growing wet AMD market. We are positioning CLS-AX for real-world success by focusing on a ...

Siloton’s handheld OCT system could soon be used for home-based monitoring of retinal disease, and may one day find its way onto future space missions ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Reduced well-being and loss of productivity were contributors to the high economic burden in patients with late-stage age-related macular degeneration (AMD) living in the US, Germany, and Bulgaria.

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of ...

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

SG&A expenses were $122.0 million for the third quarter of 2024, compared to $145.7 million for the same period in 2023. The decrease was primarily attributable to decreases in personnel related costs ...

HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration: Shanghai Tuesday, November 5, 2024, 09:00 Hrs [IST] HuidaGene Therapeutic ...